<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM FINANCIAL
STATEMENTS FOR THE YEAR ENDED DECEMBER 31, 1996 AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH FINANCIAL STATMENTS.
</LEGEND>
       
                             
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                       1,811,182
<SECURITIES>                                         0
<RECEIVABLES>                                8,799,452
<ALLOWANCES>                                 1,339,000
<INVENTORY>                                 13,188,627
<CURRENT-ASSETS>                            23,915,512
<PP&E>                                      42,801,522
<DEPRECIATION>                              13,499,466
<TOTAL-ASSETS>                              53,633,856
<CURRENT-LIABILITIES>                       14,116,414
<BONDS>                                      9,989,461
<COMMON>                                       146,035
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          6
<OTHER-SE>                                  27,639,223
<TOTAL-LIABILITY-AND-EQUITY>                53,633,856
<SALES>                                     43,855,014
<TOTAL-REVENUES>                            43,855,014
<CGS>                                       31,679,577
<TOTAL-COSTS>                               34,984,369
<OTHER-EXPENSES>                            26,616,427<F1>
<LOSS-PROVISION>                             1,213,808
<INTEREST-EXPENSE>                           1,850,446
<INCOME-PRETAX>                           (20,810,036)
<INCOME-TAX>                                 3,901,000<F2>
<INCOME-CONTINUING>                       (24,711,036)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                              (25,640,507)
<EPS-PRIMARY>                                   (2.44)
<EPS-DILUTED>                                   (2.44)
<FN>
<F1>INCLUDES A ONE-TIME, NON-CASH CHARGE OF $8.6 MILLION FOR THE RECORDING OF
PURCHASE OF IN-PROCESS RESEARCH AND DEVELOPMENT IN CONNECTION WITH THE
COMPANY'S ACQUISITION OF HALLMARK PHARMACEUTICALS, INC.
<F2>THE $3.9 MILLION OF INCOME TAX EXPENSE WAS RECORDED TO RESTORE FULLY THE
VALUATION ALLOWANCE ON THE COMPANY'S DEFERRED TAX ASSETS, IN ACCORDANCE WITH
SFAS 109.
</FN>